Abstract
This article discusses the medical/therapeutical responses to the COVID-19 pandemic and their political economy context. First, the very quick development of several vaccines highlights the richness of the basic knowledge waiting for therapeutical exploitation. Such knowledge has largely originated in public or non-profit institutions. Second, symmetrically, there is longer-term evidence that the private sector (essentially big pharma) has decreased its investment in basic research in general and has long been uninterested in vaccines in particular. Only when flooded with an enormous amount of public money did it become eager to undertake applied research, production scale-up and testing. Third, the political economy of the underlying public-private relationship reveals a profound dysfunctionality with the public being unable to determine the rates and direction of innovation, but at the same time confined to the role of payer of first and last resort, with dire consequences for both advanced, and more so developing countries. Fourth, on normative grounds, measures like ad hoc patent waivers are certainly welcome, but this will not address the fundamental challenge, involving a deep reform of the intellectual property rights regimes and their international protection.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Angell, M. (2004), The Truth about the Drug Companies: How They Deceive Us and What to Do about It, Random House.
Arora, A., S. Belenzon and A. Patacconi (2018), The decline of science in corporate R&D, Strategic Management Journal, 39(1), 3–32.
Apuzzo, M. and S. Gebrekidan (2021, 21 March), Rich Countries Signed Away a Chance to Vaccinate the World, The New York Times.
Bellomo, N., R. Bingham, M. A. Chaplain, G. Dosi, G. Forni, D. A. Knopoff, J. Lowengrub, R. Twarock and M. E. Virgillito (2020), A multi-scale model of virus pandemic: Heterogeneous interactive entities in a globally connected world, Mathematical Models and Methods in Applied Sciences, 30(08), 1591–1651.
Best, M. and J. Bradley (2020), World War II to Covid-19: Been Here Before and Done Better, Institute for New Economic Thinking.
Brock, W. A. and M. S. Taylor (2005), Economic growth and the environment: a review of theory and empirics, Handbook of Economic Growth, 1, 1749–1821.
Chataway, J., S. Brusoni, E. Cacciatori, R. Hanlin and L. Orsenigo (2007), The International AIDS Vaccine Initiative (IAVI) in a changing landscape of vaccine development: a public/private partnership as knowledge broker and integrator, The European Journal of Development Research, 19(1), 100–117.
Cimoli, M., G. Dosi, K. E. Maskus, R. L. Okediji, J. H. Reichman and J. Stiglitz (eds.) (2014), Intellectual property rights: legal and economic challenges for development, Oxford University Press.
Cleary, E. G., J. M. Beierlein, N. S. Khanuja, L. M. McNamee and F. D. Ledley (2018), Contribution of NIH funding to new drug approvals 2010–2016, Proceedings of the National Academy of Sciences, 115(10), 2329–2334.
Coriat, B., F. Orsi and C. d’Almeida (2006), TRIPS and the international public health controversies: issues and challenges, Industrial and corporate change, 15(6), 1033–1062.
Coriat, B. (2020), La pandémie, l’Anthropocène et le bien commun, Les Liens Qui Libèrent.
Crutzen, P. J. (2006), The “anthropocene”, in E. Ehlers and T. Krafft (eds.), Earth System Science in the Anthropocene, Springer, 13–18.
Dosi, G., L. Fanti and M. E. Virgillito (2020), Unequal societies in usual times, unjust societies in pandemic ones, Journal of Industrial and Business Economics, 47(3), 371–389.
Dosi, G. and J. E. Stiglitz (2014), The Role of Intellectual Property Rights in the Development Process, with Some Lessons from Developed Countries: An Introduction, in M. Cimoli, G. Dosi, K. E. Maskus, R. L. Okediji, J. H. Reichman and J. Stiglitz (eds.) (2014), Intellectual property rights: legal and economic challenges for development, Oxford University Press, 1–55.
Dosi, G., L. Marengo and C. Pasquali (2006), How much should society fuel the greed of innovators?: On the relations between appropriability, opportunities and rates of innovation, Research Policy, 35(8), 1110–1121.
Florio, M. (2019), Investing in science: Social cost-benefit analysis of research infrastructures, MIT Press.
Florio, M. (2020), Biomed Europa: after the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly, CIRIEC Working Papers, 2020/08.
Gross, D. P. and B. N. Sampat (2020), Organizing Crisis Innovation: Lessons from World War II, National Bureau of Economic Research Working Paper, 27909.
Gross, D. P. and B. N. Sampat (2021), The Economics of Crisis Innovation Policy: A Historical Perspective, National Bureau of Economic Research Working Paper, 28335.
Lancet Commission on COVID-19 (2021), Operation Warp Speed: Implications for Global Vaccine Security, The Lancet Global Health.
Nelson, R. R. (ed.) (2005), The limits of market organization, Russell Sage Foundation.
Orsenigo, L., G. Dosi and M. Mazzucato (2006), The Dynamics of Knowledge Accumulation, Regulation, and Appropriability in the Pharma-Biotech Sector: Policy Issues, in M. Mazzucato and G. Dosi (eds.) (2006), Knowledge Accumulation and Industry Evolution, Cambridge University Press, 402–431.
Rawat, K., P. Kumari and L. Saha (2021), COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies, European journal of pharmacology, 892, 173751.
So, A. D., B. N. Sampat, A. K. Rai, R. Cook-Deegan, J. H. Reichman, R. Weissman and A. Kapczynski (2014), Is Bayh-Dole good for developing countries? Lessons from the US experience, in M. Cimoli, G. Dosi, K. E. Maskus, R. L. Okediji, J. H. Reichman and J. Stiglitz (eds.) (2014), Intellectual property rights: legal and economic challenges for development, Oxford University Press, 201–215.
Walker, N. (2020), Drug Approval Trends: Significant Acceleration in Recent Years, Pharma’s Almanac, PAP-Q2-20-NI-001.
Author information
Authors and Affiliations
Corresponding author
Additional information
Giovanni Dosi, Sant’Anna School of Advanced Studies, Pisa, Italy.
Rights and permissions
Open Access: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Open Access funding provided by ZBW — Leibniz Information Centre for Economics.
About this article
Cite this article
Dosi, G. Policy Lessons From Medical Responses to the COVID-19 Crisis. Intereconomics 56, 337–340 (2021). https://doi.org/10.1007/s10272-021-1009-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10272-021-1009-2